IVAN ROSAS to Lymphangioleiomyomatosis
This is a "connection" page, showing publications IVAN ROSAS has written about Lymphangioleiomyomatosis.
Connection Strength
1.543
-
Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion. J Bras Pneumol. 2023; 49(2):e20220356.
Score: 0.209
-
The lung microbiome in end-stage Lymphangioleiomyomatosis. Respir Res. 2021 Oct 26; 22(1):277.
Score: 0.188
-
Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J. 2020 05; 55(5).
Score: 0.170
-
Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells. Chest. 2019 12; 156(6):1137-1148.
Score: 0.160
-
Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis. Orphanet J Rare Dis. 2019 03 29; 14(1):72.
Score: 0.157
-
Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest. 2018 11; 154(5):1070-1082.
Score: 0.151
-
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res. 2017 03 15; 77(6):1492-1502.
Score: 0.136
-
Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest. 2017 06; 151(6):1302-1310.
Score: 0.136
-
Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J. 2015 Sep; 46(3):783-94.
Score: 0.121
-
Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. PLoS One. 2014; 9(10):e104809.
Score: 0.116